U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Chou R, Cuevas C, Fu R, et al. Imaging Techniques for the Diagnosis and Staging of Hepatocellular Carcinoma [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Oct. (Comparative Effectiveness Reviews, No. 143.)

Cover of Imaging Techniques for the Diagnosis and Staging of Hepatocellular Carcinoma

Imaging Techniques for the Diagnosis and Staging of Hepatocellular Carcinoma [Internet].

Show details

Appendix AIncluded Studies

1.
Addley HC, Griffin N, Shaw AS, et al. Accuracy of hepatocellular carcinoma detection on multidetector CT in a transplant liver population with explant liver correlation. Clin Radiol. 2011 Apr;66(4):349–56. [PubMed: 21295772]
2.
Ahn SS, Kim M-J, Lim JS, et al. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology. 2010 May;255(2):459–66. [PubMed: 20413759]
3.
Akai H, Kiryu S, Matsuda I, et al. Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol. 2011 Nov;80(2):310–5. [PubMed: 20732773]
4.
Alaboudy A, Inoue T, Hatanaka K, et al. Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid(R)-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography. Oncology. 2011;81(Suppl 1):66–72. [PubMed: 22212939]
5.
An C, Park MS, Kim D, et al. Added value of subtraction imaging in detecting arterial enhancement in small (<3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma. Eur Radiol. 2013;23:924–30. [PubMed: 23138382]
6.
An C, Park M-S, Jeon H-M, et al. Prediction of the histopathological grade of hepatocellular carcinoma using qualitative diffusion-weighted, dynamic, and hepatobiliary phase MRI. Eur Radiol. 2012 Aug;22(8):1701–8. [PubMed: 22434421]
7.
Baccarani U, Adani GL, Avellini C, et al. Comparison of clinical and pathological staging and long-term results of liver transplantation for hepatocellular carcinoma in a single transplant center. Transplant Proc. 2006 May;38(4):1111–3. [PubMed: 16757280]
8.
Baek CK, Choi JY, Kim KA, et al. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. Clin Radiol. 2012 Feb;67(2):148–56. [PubMed: 21920517]
9.
Baird AJ, Amos GJ, Saad NF, et al. Retrospective audit to determine the diagnostic accuracy of Primovist-enhanced MRI in the detection of hepatocellular carcinoma in cirrhosis with explant histopathology correlation. J Med Imaging Radiat Oncol. 2013;57(3):314–20. [PubMed: 23721140]
10.
Bartolozzi C, Donati F, Cioni D, et al. MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis. Eur Radiol. 2000;10(11):1697–702. [PubMed: 11097390]
11.
Bennett GL, Krinsky GA, Abitbol RJ, et al. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. AJR Am J Roentgenol. 2002 Jul;179(1):75–80. [PubMed: 12076908]
12.
Bhattacharjya S, Bhattacharjya T, Quaglia A, et al. Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of pre-operative imaging, explant histology and prognostic histologic indicators. Dig Surg. 2004;21(2):152–9. discussion 9–60. [PubMed: 15166485]
13.
Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003 Oct;38(4):1034–42. [PubMed: 14512891]
14.
Catala V, Nicolau C, Vilana R, et al. Characterization of focal liver lesions: comparative study of contrast-enhanced ultrasound versus spiral computed tomography. Eur Radiol. 2007 Apr;17(4):1066–73. [PubMed: 17072617]
15.
Cereser L, Furlan A, Bagatto D, et al. Comparison of portal venous and delayed phases of gadolinium-enhanced magnetic resonance imaging study of cirrhotic liver for the detection of contrast washout of hypervascular hepatocellular carcinoma. J Comput Assist Tomogr. 2010;34(5):706–11. [PubMed: 20861773]
16.
Chalasani N, Horlander JC Sr, Said A, et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol. 1999 Oct;94(10):2988–93. [PubMed: 10520857]
17.
Chen MH, Wu W, Yang W, et al. The use of contrast-enhanced ultrasonography in the selection of patients with hepatocellular carcinoma for radio frequency ablation therapy. J Ultrasound Med. 2007;26(8):1055–63. [PubMed: 17646367]
18.
Chen MH, Yang W, Yan K, et al. The role of contrast-enhanced ultrasound in planning treatment protocols for hepatocellular carcinoma before radiofrequency ablation. Clin Radiol. 2007 Aug;62(8):752–60. [PubMed: 17604763]
19.
Chen Y-K, Hsieh D-S, Liao C-S, et al. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res. 2005 Nov–Dec;25(6C):4719–25. [PubMed: 16334166]
20.
Cheung TT, Chan SC, Ho CL, et al. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma? Liver Transpl. 2011 Oct;17(10):1218–25. [PubMed: 21688383]
21.
Cheung TT, Ho CL, Lo CM, et al. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of milan criteria: Surgeon’s perspective. J Nucl Med. 2013;54(2):192–200. [PubMed: 23321459]
22.
Choi D, Kim SH, Lim JH, et al. Detection of hepatocellular carcinoma: combined T2-weighted and dynamic gadolinium-enhanced MRI versus combined CT during arterial portography and CT hepatic arteriography. J Comput Assist Tomogr. 2001 Sep–Oct;25(5):777–85. [PubMed: 11584240]
23.
Choi SH, Lee JM, Yu NC, et al. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol. 2008 Aug;191(2):529–36. [PubMed: 18647927]
24.
Chou C-T, Chen R-C, Chen W-T, et al. Characterization of hyperintense nodules on T1-weighted liver magnetic resonance imaging: comparison of Ferucarbotran-enhanced MRI with accumulation-phase FS-T1WI and gadolinium-enhanced MRI. J Chin Med Assoc. 2011 Feb;74(2):62–8. [PubMed: 21354082]
25.
Chung J, Yu J-S, Kim DJ, et al. Hypervascular hepatocellular carcinoma in the cirrhotic liver: diffusion-weighted imaging versus superparamagnetic iron oxide-enhanced MRI. Magn Reson Imaging. 2011 Nov;29(9):1235–43. [PubMed: 21907517]
26.
Chung S-H, Kim M-J, Choi J-Y, et al. Comparison of two different injection rates of gadoxetic acid for arterial phase MRI of the liver. J Magn Reson Imaging. 2010 Feb;31(2):365–72. [PubMed: 20099350]
27.
Colagrande S, Fargnoli R, Dal Pozzo F, et al. Value of hepatic arterial phase CT versus lipiodol ultrafluid CT in the detection of hepatocellular carcinoma. J Comput Assist Tomogr. 2000 Nov–Dec;24(6):878–83. [PubMed: 11105704]
28.
Dai Y, Chen MH, Fan ZH, et al. Diagnosis of small hepatic nodules detected by surveillance ultrasound in patients with cirrhosis: Comparison between contrast-enhanced ultrasound and contrast-enhanced helical computed tomography. Hepatol Res. 2008 Mar;38(3):281–90. [PubMed: 17908168]
29.
de Ledinghen V, Laharie D, Lecesne R, et al. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol. 2002 Feb;14(2):159–65. [PubMed: 11981340]
30.
Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998 May;133(5):510–5. discussion 5–6. [PubMed: 9605913]
31.
Denecke T, Grieser C, Froling V, et al. Multislice computed tomography using a triple-phase contrast protocol for preoperative assessment of hepatic tumor load in patients with hepatocellular carcinoma before liver transplantation. Transpl Int. 2009 Apr;22(4):395–402. [PubMed: 19000231]
32.
Di Martino M, De Filippis G, De Santis A, et al. Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol. 2013;23:887–96. [PubMed: 23179521]
33.
Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010 Sep;256(3):806–16. [PubMed: 20720069]
34.
D’Onofrio M, Rozzanigo U, Masinielli BM, et al. Hypoechoic focal liver lesions: characterization with contrast enhanced ultrasonography. J Clin Ultrasound. 2005 May;33(4):164–72. [PubMed: 15856516]
35.
Doyle DJ, O’Malley ME, Jang H-J, et al. Value of the unenhanced phase for detection of hepatocellular carcinomas 3 cm or less when performing multiphase computed tomography in patients with cirrhosis. J Comput Assist Tomogr. 2007 Jan–Feb;31(1):86–92. [PubMed: 17259838]
36.
Eckel F, Herrmann K, Schmidt S, et al. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med. 2009 Sep;50(9):1441–7. [PubMed: 19690030]
37.
Egger C, Goertz RS, Strobel D, et al. Dynamic contrast-enhanced ultrasound (DCE-US) for easy and rapid evaluation of hepatocellular carcinoma compared to dynamic contrast-enhanced computed tomography (DCE-CT)--a pilot study. Ultraschall Med. 2012;33(6):587–92. [PubMed: 23154871]
38.
Filippone A, Cianci R, Patriarca G, et al. The Value of Gadoxetic Acid-Enhanced Hepatospecific Phase MR Imaging for Characterization of Hepatocellular Nodules in the Cirrhotic Liver. European Journal of Clinical & Medical Oncology. 2010;2(4):1–8.
39.
Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008 Jan;47(1):97–104. [Erratum appears in Hepatology. 2008 Feb;47(2):769] [PubMed: 18069697]
40.
Fowler KJ, Karimova EJ, Arauz AR, et al. Validation of organ procurement and transplant network (OPTN)/united network for organ sharing (UNOS) criteria for imaging diagnosis of hepatocellular carcinoma. Transplantation. 2013;95(12):1506–11. [PubMed: 23778569]
41.
Fracanzani AL, Burdick L, Borzio M, et al. Contrast-enhanced Doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology. 2001 Dec;34(6):1109–12. [PubMed: 11731999]
42.
Freeman RB, Mithoefer A, Ruthazer R, et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database. Liver Transpl. 2006 Oct;12(10):1504–11. [PubMed: 16952174]
43.
Freeny PC, Grossholz M, Kaakaji K, et al. Significance of hyperattenuating and contrast-enhancing hepatic nodules detected in the cirrhotic liver during arterial phase helical CT in pre-liver transplant patients: radiologic-histopathologic correlation of explanted livers. Abdom Imaging. 2003 May–Jun;28(3):333–46. [PubMed: 12719903]
44.
Furuse J, Maru Y, Yoshino M, et al. Assessment of arterial tumor vascularity in small hepatocellular carcinoma. Comparison between color doppler ultrasonography and radiographic imagings with contrast medium: dynamic CT, angiography, and CT hepatic arteriography. Eur J Radiol. 2000 Oct;36(1):20–7. [PubMed: 10996754]
45.
Gaiani S, Celli N, Piscaglia F, et al. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol. 2004 Sep;41(3):421–6. [PubMed: 15336445]
46.
Gambarin-Gelwan M, Wolf DC, Shapiro R, et al. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol. 2000 Jun;95(6):1535–8. [PubMed: 10894592]
47.
Gatto A, De Gaetano AM, Giuga M, et al. Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging. Abdom Imaging. 2013;38(4):736–44. [PubMed: 22986351]
48.
Giorgio A, De Stefano G, Coppola C, et al. Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Res. 2007 Nov–Dec;27(6C):4263–9. [PubMed: 18214030]
49.
Giorgio A, Ferraioli G, Tarantino L, et al. Contrast-enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: Comparison with contrast-enhanced helical CT appearance. AJR Am J Roentgenol. 2004;183(5):1319–26. [PubMed: 15505297]
50.
Golfieri R, Marini E, Bazzocchi A, et al. Small (≤ 3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT. Radiol Med (Torino). 2009 Dec;114(8):1239–66. [PubMed: 19697104]
51.
Goshima S, Kanematsu M, Matsuo M, et al. Nodule-in-nodule appearance of hepatocellular carcinomas: comparison of gadolinium-enhanced and ferumoxides-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2004 Aug;20(2):250–5. [PubMed: 15269950]
52.
Goto E, Masuzaki R, Tateishi R, et al. Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma. J Gastroenterol. 2012;47(4):477–85. [PubMed: 22200940]
53.
Guo L, Liang C, Yu T, et al. 3 T MRI of hepatocellular carcinomas in patients with cirrhosis: does T2-weighted imaging provide added value? Clin Radiol. 2012 Apr;67(4):319–28. [PubMed: 22099524]
54.
Haradome H, Grazioli L, Tinti R, et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging. 2011 Jul;34(1):69–78. [PubMed: 21598343]
55.
Hardie AD, Kizziah MK, Boulter DJ. Diagnostic accuracy of diffusion-weighted MRI for identifying hepatocellular carcinoma with liver explant correlation. J Med Imaging Radiat Oncol. 2011 Aug;55(4):362–7. [PubMed: 21843170]
56.
Hardie AD, Kizziah MK, Rissing MS. Can the patient with cirrhosis be imaged for hepatocellular carcinoma without gadolinium?: Comparison of combined T2-weighted, T2*-weighted, and diffusion-weighted MRI with gadolinium-enhanced MRI using liver explantation standard. J Comput Assist Tomogr. 2011 Nov–Dec;35(6):711–5. [PubMed: 22082541]
57.
Hardie AD, Nance JW, Boulter DJ, et al. Assessment of the diagnostic accuracy of T2*-weighted MR imaging for identifying hepatocellular carcinoma with liver explant correlation. Eur J Radiol. 2011 Dec;80(3):e249–52. [PubMed: 21112710]
58.
Hatanaka K, Kudo M, Minami Y, et al. Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology. 2008;51(Suppl 1):61–9. [PubMed: 18544950]
59.
Hecht EM, Holland AE, Israel GM, et al. Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology. 2006 May;239(2):438–47. [PubMed: 16641353]
60.
Hidaka M, Takatsuki M, Okudaira S, et al. The expression of transporter OATP2/OATP8 decreases in undetectable hepatocellular carcinoma by Gd-EOB-MRI in the explanted cirrhotic liver. Hepatology International. 2012:1–7. [PubMed: 26201798]
61.
Higashihara H, Osuga K, Onishi H, et al. Diagnostic accuracy of C-arm CT during selective transcatheter angiography for hepatocellular carcinoma: comparison with intravenous contrast-enhanced, biphasic, dynamic MDCT. Eur Radiol. 2012 Apr;22(4):872–9. [PubMed: 22120061]
62.
Hirakawa M, Yoshimitsu K, Irie H, et al. Performance of radiological methods in diagnosing hepatocellular carcinoma preoperatively in a recipient of living related liver transplantation: comparison with step section histopathology. Jpn J Radiol. 2011 Feb;29(2):129–37. [PubMed: 21359938]
63.
Ho C-l, Chen S, Yeung DWC, et al. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med. 2007 Jun;48(6):902–9. [PubMed: 17504862]
64.
Ho C-L, Yu SCH, Yeung DWC. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003 Feb;44(2):213–21. [PubMed: 12571212]
65.
Hori M, Murakami T, Kim T, et al. Detection of hypervascular hepatocellular carcinoma: comparison of SPIO-enhanced MRI with dynamic helical CT. J Comput Assist Tomogr. 2002 Sep–Oct;26(5):701–10. [PubMed: 12439302]
66.
Hori M, Murakami T, Oi H, et al. Sensitivity in detection of hypervascular hepatocellular carcinoma by helical CT with intra-arterial injection of contrast medium, and by helical CT and MR imaging with intravenous injection of contrast medium. Acta Radiol. 1998 Mar;39(2):144–51. [PubMed: 9529444]
67.
Hwang J, Kim SH, Lee MW, et al. Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT. Br J Radiol. 2012 Jul;85(1015):e314–22. [PMC free article: PMC3474077] [PubMed: 22167508]
68.
Hwang KH, Choi D-J, Lee S-Y, et al. Evaluation of patients with hepatocellular carcinomas using [(11)C]acetate and [(18)F]FDG PET/CT: A preliminary study. Appl Radiat Isot. 2009 Jul–Aug;67(7–8):1195–8. [PubMed: 19342249]
69.
Iannaccone R, Laghi A, Catalano C, et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology. 2005 Feb;234(2):460–7. [PubMed: 15671002]
70.
Iavarone M, Sangiovanni A, Forzenigo LV, et al. Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology. 2010 Nov;52(5):1723–30. [PubMed: 20842697]
71.
Ichikawa T, Kitamura T, Nakajima H, et al. Hypervascular hepatocellular carcinoma: can double arterial phase imaging with multidetector CT improve tumor depiction in the cirrhotic liver? AJR Am J Roentgenol. 2002 Sep;179(3):751–8. [PubMed: 12185057]
72.
Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010 Mar;45(3):133–41. [PubMed: 20098330]
73.
Ijichi H, Shirabe K, Taketomi A, et al. Clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma. Hepatol Res. 2013;43(5):481–7. [PubMed: 23145869]
74.
Imamura M, Shiratori Y, Shiina S, et al. Power Doppler sonography for hepatocellular carcinoma: factors affecting the power Doppler signals of the tumors. Liver. 1998 Dec;18(6):427–33. [PubMed: 9869398]
75.
Inoue T, Kudo M, Hatanaka K, et al. Imaging of hepatocellular carcinoma: Qualitative and quantitative analysis of postvascular phase contrast-enhanced ultrasonography with sonazoid. Oncology. 2008;75(SUPPL 1):48–54. [PubMed: 19092272]
76.
Inoue T, Kudo M, Komuta M, et al. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol. 2012 Sep;47(9):1036–47. [PubMed: 22526270]
77.
Inoue T, Kudo M, Maenishi O, et al. Value of liver parenchymal phase contrast-enhanced sonography to diagnose premalignant and borderline lesions and overt hepatocellular carcinoma. AJR Am J Roentgenol. 2009 Mar;192(3):698–705. [PubMed: 19234266]
78.
Ito K, Fujita T, Shimizu A, et al. Multiarterial phase dynamic MRI of small early enhancing hepatic lesions in cirrhosis or chronic hepatitis: Differentiating between hypervascular hepatocellular carcinomas and pseudolesions. AJR Am J Roentgenol. 2004;183(3):699–705. [PubMed: 15333358]
79.
Iwazawa J, Ohue S, Hashimoto N, et al. Detection of hepatocellular carcinoma: comparison of angiographic C-arm CT and MDCT. AJR Am J Roentgenol. 2010 Oct;195(4):882–7. [PubMed: 20858813]
80.
Jang HJ, Kim TK, Khalili K, et al. Characterization of 1- to 2-cm liver nodules detected on hcc surveillance ultrasound according to the criteria of the american association for the study of liver disease: Is quadriphasic CT necessary? AJR Am J Roentgenol. 2013;201(2):314–21. [PubMed: 23883211]
81.
Jang HJ, Kim TK, Wilson SR. Small nodules (1–2 cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound. Eur J Radiol. 2009 Dec;72(3):418–24. [PubMed: 18834687]
82.
Jang HJ, Lim JH, Lee SJ, et al. Hepatocellular carcinoma: are combined CT during arterial portography and CT hepatic arteriography in addition to triple-phase helical CT all necessary for preoperative evaluation? Radiology. 2000 May;215(2):373–80. [PubMed: 10796910]
83.
Jeng C-M, Kung C-H, Wang Y-C, et al. Spiral biphasic contrast-enhanced computerized tomography in the diagnosis of hepatocellular carcinoma. J Formos Med Assoc. 2002 Aug;101(8):588–92. [PubMed: 12440092]
84.
Jeng L-B, Changlai S-P, Shen Y-Y, et al. Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepatogastroenterology. 2003 Nov–Dec;50(54):2154–6. [PubMed: 14696485]
85.
Jeong MG, Yu JS, Kim KW, et al. Early homogeneously enhancing hemangioma versus hepatocellular carcinoma: differentiation using quantitative analysis of multiphasic dynamic magnetic resonance imaging. Yonsei Med J. 1999 Jun;40(3):248–55. [PubMed: 10412337]
86.
Jeong WK, Byun JH, Lee SS, et al. Gadobenate dimeglumine-enhanced liver MR imaging in cirrhotic patients: quantitative and qualitative comparison of 1-hour and 3-hour delayed images. J Magn Reson Imaging. 2011 Apr;33(4):889–97. [PubMed: 21448954]
87.
Jin Y, Nah S, Lee J, et al. Utility of Adding Primovist Magnetic Resonance Imaging to Analysis of Hepatocellular Carcinoma by Liver Dynamic Computed Tomography. Clin Gastroenterol Hepatol. 2013;11(2):187–92. [PubMed: 23142203]
88.
Kakihara D, Nishie A, Harada N, et al. Performance of gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in recipients of living-related-liver-transplantation: Comparison with dynamic multidetector row computed tomography and angiography-assisted computed tomography. J Magn Reson Imaging. 2013 [PubMed: 24259437]
89.
Kamura T, Kimura M, Sakai K, et al. Small hypervascular hepatocellular carcinoma versus hypervascular pseudolesions: Differential diagnosis on MRI. Abdom Imaging. 2002;27(3):315–24. [PubMed: 12173363]
90.
Kang BK, Lim JH, Kim SH, et al. Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology. 2003 Jan;226(1):79–85. [PubMed: 12511672]
91.
Kawada N, Ohkawa K, Tanaka S, et al. Improved diagnosis of well-differentiated hepatocellular carcinoma with gadolinium ethoxybenzyl diethylene triamine pentaacetic acid-enhanced magnetic resonance imaging and Sonazoid contrast-enhanced ultrasonography. Hepatol Res. 2010;40(9):930–6. [PubMed: 20887598]
92.
Kawaoka T, Aikata H, Takaki S, et al. FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res. 2009;39(2):134–42. [PubMed: 19208034]
93.
Kawata S, Murakami T, Kim T, et al. Multidetector CT: diagnostic impact of slice thickness on detection of hypervascular hepatocellular carcinoma. AJR Am J Roentgenol. 2002 Jul;179(1):61–6. [PubMed: 12076906]
94.
Khalili K, Kim TK, Jang H-J, et al. Optimization of imaging diagnosis of 1–2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol. 2011 Apr;54(4):723–8. [PubMed: 21156219]
95.
Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000 May;32(5):792–7. [PubMed: 10845666]
96.
Kim AY, Kim YK, Lee MW, et al. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis. Acta Radiol. 2012 Oct 1;53(8):830–8. [PubMed: 22847903]
97.
Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med. 2001 Feb;20(2):99–104. [PubMed: 11211142]
98.
Kim DJ, Yu JS, Kim JH, et al. Small hypervascular hepatocellular carcinomas: value of diffusion-weighted imaging compared with “washout” appearance on dynamic MRI. Br J Radiol. 2012 Oct;85(1018):e879–86. [PMC free article: PMC3474029] [PubMed: 22573299]
99.
Kim KW, Lee JM, Klotz E, et al. Quantitative CT color mapping of the arterial enhancement fraction of the liver to detect hepatocellular carcinoma. Radiology. 2009 Feb;250(2):425–34. [PubMed: 19188314]
100.
Kim M-J, Lee M, Choi J-Y, et al. Imaging features of small hepatocellular carcinomas with microvascular invasion on gadoxetic acid-enhanced MR imaging. Eur J Radiol. 2012 Oct;81(10):2507–12. [PubMed: 22137613]
101.
Kim PN, Choi D, Rhim H, et al. Planning ultrasound for percutaneous radiofrequency ablation to treat small (≤ 3 cm) hepatocellular carcinomas detected on computed tomography or magnetic resonance imaging: a multicenter prospective study to assess factors affecting ultrasound visibility. J Vasc Interv Radiol. 2012 May;23(5):627–34. [PubMed: 22387030]
102.
Kim SE, Lee HC, Shim JH, et al. Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2 cm in a hepatitis B virus-endemic area. Liver Int. 2011 Nov;31(10):1468–76. [PubMed: 21745284]
103.
Kim SH, Choi D, Kim SH, et al. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol. 2005 Apr;184(4):1069–76. [PubMed: 15788575]
104.
Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol. 2009 Jun;192(6):1675–81. [PubMed: 19457834]
105.
Kim SJ, Kim SH, Lee J, et al. Ferucarbotran-enhanced 3.0-T magnetic resonance imaging using parallel imaging technique compared with triple-phase multidetector row computed tomography for the preoperative detection of hepatocellular carcinoma. J Comput Assist Tomogr. 2008 May–Jun;32(3):379–85. [Erratum appears in J Comput Assist Tomogr. 2008 Jul–Aug;32(4):615] [PubMed: 18520541]
106.
Kim SK, Lim JH, Lee WJ, et al. Detection of hepatocellular carcinoma: comparison of dynamic three-phase computed tomography images and four-phase computed tomography images using multidetector row helical computed tomography. J Comput Assist Tomogr. 2002 Sep–Oct;26(5):691–8. [PubMed: 12439300]
107.
Kim T, Murakami T, Hori M, et al. Small hypervascular hepatocellular carcinoma revealed by double arterial phase CT performed with single breath-hold scanning and automatic bolus tracking. AJR Am J Roentgenol. 2002 Apr;178(4):899–904. [PubMed: 11906869]
108.
Kim TK, Lee KH, Jang H-J, et al. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1–2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology. 2011 Jun;259(3):730–8. [PubMed: 21364083]
109.
Kim YK, Kim CS, Chung GH, et al. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR Am J Roentgenol. 2006 Jan;186(1):149–57. [PubMed: 16357395]
110.
Kim YK, Kim CS, Han YM, et al. Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography. J Comput Assist Tomogr. 2009 Nov–Dec;33(6):844–50. [PubMed: 19940648]
111.
Kim YK, Kim CS, Han YM, et al. Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial? Clin Radiol. 2011 Jun;66(6):489–96. [Erratum appears in Clin Radiol. 2011 Oct;66(10):1006] [PubMed: 21367403]
112.
Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging? Invest Radiol. 2010 Nov;45(11):740–6. [PubMed: 20644488]
113.
Kim YK, Kim CS, Han YM, et al. Comparison of gadoxetic acid-enhanced MRI and superparamagnetic iron oxide-enhanced MRI for the detection of hepatocellular carcinoma. Clin Radiol. 2010 May;65(5):358–65. [PubMed: 20380933]
114.
Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: intraindividual comparison of gadoxetic acid-enhanced MRI at 3.0 and 1.5 T. Invest Radiol. 2011 Jun;46(6):383–9. [Erratum appears in Invest Radiol. 2011 Sep;46(9):600] [PubMed: 21467946]
115.
Kim YK, Kim CS, Kwak HS, et al. Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced mr imaging. J Magn Reson Imaging. 2004 Nov;20(5):826–37. [PubMed: 15503325]
116.
Kim YK, Kim CS, Lee YH, et al. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas. AJR Am J Roentgenol. 2004 May;182(5):1217–23. [PubMed: 15100122]
117.
Kim YK, Kwak HS, Han YM, et al. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography. J Comput Assist Tomogr. 2007 Sep–Oct;31(5):702–11. [PubMed: 17895780]
118.
Kim YK, Kwak HS, Kim CS, et al. Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology. 2006 Feb;238(2):531–41. [PubMed: 16371577]
119.
Kim YK, Lee YH, Kim CS, et al. Added diagnostic value of T2-weighted MR imaging to gadolinium-enhanced three-dimensional dynamic MR imaging for the detection of small hepatocellular carcinomas. Eur J Radiol. 2008 Aug;67(2):304–10. [PubMed: 17714904]
120.
Kim YK, Lee YH, Kim CS, et al. Double-dose 1.0-M gadobutrol versus standard-dose 0.5-M gadopentetate dimeglumine in revealing small hypervascular hepatocellular carcinomas. Eur Radiol. 2008 Jan;18(1):70–7. [PubMed: 17404740]
121.
Kim Y-K, Lee K-W, Cho SY, et al. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl. 2010 Jun;16(6):767–72. [PubMed: 20517911]
122.
Kitamura T, Ichikawa T, Erturk SM, et al. Detection of hypervascular hepatocellular carcinoma with multidetector-row CT: single arterial-phase imaging with computer-assisted automatic bolus-tracking technique compared with double arterial-phase imaging. J Comput Assist Tomogr. 2008 Sep–Oct;32(5):724–9. [PubMed: 18830101]
123.
Kondo H, Kanematsu M, Itoh K, et al. Does T2-weighted MR imaging improve preoperative detection of malignant hepatic tumors? Observer performance study in 49 surgically proven cases. Magn Reson Imaging. 2005 Jan;23(1):89–95. [PubMed: 15733793]
124.
Korenaga K, Korenaga M, Furukawa M, et al. Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: Comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images. J Gastroenterol. 2009;44(7):733–41. [PubMed: 19387532]
125.
Koushima Y, Ebara M, Fukuda H, et al. Small hepatocellular carcinoma: assessment with T1-weighted spin-echo magnetic resonance imaging with and without fat suppression. Eur J Radiol. 2002 Jan;41(1):34–41. [PubMed: 11750150]
126.
Krinsky GA, Lee VS, Theise ND, et al. Transplantation for hepatocellular carcinoma and cirrhosis: Sensitivity of magnetic resonance imaging. Liver Transpl. 2002;8(12):1156–64. [PubMed: 12474156]
127.
Krinsky GA, Lee VS, Theise ND, et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology. 2001 May;219(2):445–54. [PubMed: 11323471]
128.
Kumano S, Uemura M, Haraikawa T, et al. Efficacy of double arterial phase dynamic magnetic resonance imaging with the sensitivity encoding technique versus dynamic multidetector-row helical computed tomography for detecting hypervascular hepatocellular carcinoma. Jpn J Radiol. 2009 Jul;27(6):229–36. [PubMed: 19626408]
129.
Kunishi Y, Numata K, Morimoto M, et al. Efficacy of fusion imaging combining sonography and hepatobiliary phase MRI with Gd-EOB-DTPA to detect small hepatocellular carcinoma. AJR Am J Roentgenol. 2012 Jan;198(1):106–14. [PubMed: 22194485]
130.
Kwak H-S, Lee J-M, Kim C-S. Preoperative detection of hepatocellular carcinoma: comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography. Eur Radiol. 2004 Mar;14(3):447–57. [PubMed: 14531005]
131.
Kwak H-S, Lee J-M, Kim Y-K, et al. Detection of hepatocellular carcinoma: comparison of ferumoxides-enhanced and gadolinium-enhanced dynamic three-dimensional volume interpolated breath-hold MR imaging. Eur Radiol. 2005 Jan;15(1):140–7. [PubMed: 15449000]
132.
Laghi A, Iannaccone R, Rossi P, et al. Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. Radiology. 2003 Feb;226(2):543–9. [PubMed: 12563152]
133.
Lauenstein TC, Salman K, Morreira R, et al. Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. AJR Am J Roentgenol. 2007 Sep;189(3):663–70. [PubMed: 17715115]
134.
Lee CH, Kim KA, Lee J, et al. Using low tube voltage (80kVp) quadruple phase liver CT for the detection of hepatocellular carcinoma: two-year experience and comparison with Gd-EOB-DTPA enhanced liver MRI. Eur J Radiol. 2012 Apr;81(4):e605–11. [PubMed: 22297180]
135.
Lee DH, Kim SH, Lee JM, et al. Diagnostic performance of multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and dual-contrast magnetic resonance imaging in predicting the appropriateness of a transplant recipient based on milan criteria: correlation with histopathological findings. Invest Radiol. 2009 Jun;44(6):311–21. [PubMed: 19462486]
136.
Lee J, Won JL, Hyo KL, et al. Early hepatocellular carcinoma: Three-phase helical CT features of 16 patients. Korean J Radiol. 2008;9(4):325–32. [PMC free article: PMC2627272] [PubMed: 18682670]
137.
Lee JE, Jang JY, Jeong SW, et al. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan. World J Gastroenterol. 2012 Jun 21;18(23):2979–87. [PMC free article: PMC3380326] [PubMed: 22736922]
138.
Lee J-M, Kim I-H, Kwak H-S, et al. Detection of small hypervascular hepatocellular carcinomas in cirrhotic patients: comparison of superparamagnetic iron oxide-enhanced MR imaging with dual-phase spiral CT. Korean J Radiol. 2003 Jan–Mar;4(1):1–8. [PMC free article: PMC2698053] [PubMed: 12679628]
139.
Lee JY, Kim SH, Jeon YH, et al. Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: initial experience. J Comput Assist Tomogr. 2010 Jan;34(1):127–34. [PubMed: 20118735]
140.
Lee MH, Kim SH, Park MJ, et al. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol. 2011 Nov;197(5):W868–75. [PubMed: 22021534]
141.
Lee MW, Kim YJ, Park HS, et al. Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. AJR Am J Roentgenol. 2010 May;194(5):W396–400. [PubMed: 20410384]
142.
Li CS, Chen RC, Tu HY, et al. Imaging well-differentiated hepatocellular carcinoma with dynamic triple-phase helical computed tomography. Br J Radiol. 2006 Aug;79(944):659–65. [PubMed: 16641423]
143.
Li R, Guo Y, Hua X, et al. Characterization of focal liver lesions: comparison of pulse-inversion harmonic contrast-enhanced sonography with contrast-enhanced CT. J Clin Ultrasound. 2007 Mar–Apr;35(3):109–17. [PubMed: 17295272]
144.
Li S, Beheshti M, Peck-Radosavljevic M, et al. Comparison of (11)C-acetate positron emission tomography and (67)Gallium citrate scintigraphy in patients with hepatocellular carcinoma. Liver Int. 2006 Oct;26(8):920–7. [PubMed: 16953831]
145.
Liangpunsakul S, Agarwal D, Horlander JC, et al. Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis C cirrhotics awaiting for liver transplantation. Transplant Proc. 2003 Dec;35(8):2995–7. [PubMed: 14697959]
146.
Libbrecht L, Bielen D, Verslype C, et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl. 2002 Sep;8(9):749–61. [PubMed: 12200773]
147.
Lim JH, Choi D, Kim SH, et al. Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol. 2002 Jul;179(1):67–73. [PubMed: 12076907]
148.
Lim JH, Kim CK, Lee WJ, et al. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR Am J Roentgenol. 2000 Sep;175(3):693–8. [PubMed: 10954452]
149.
Lim JH, Kim SH, Lee WJ, et al. Ultrasonographic detection of hepatocellular carcinoma: Correlation of preoperative ultrasonography and resected liver pathology. Clin Radiol. 2006;61(2):191–7. [PubMed: 16439225]
150.
Lin M-T, Chen C-L, Wang C-C, et al. Diagnostic sensitivity of hepatocellular carcinoma imaging and its application to non-cirrhotic patients. J Gastroenterol Hepatol. 2011 Apr;26(4):745–50. [PubMed: 21418303]
151.
Lin W-Y, Tsai S-C, Hung G-U. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nuclear Medicine Communications. 2005 Apr;26(4):315–21. [PubMed: 15753790]
152.
Liu WC, Lim JH, Park CK, et al. Poor sensitivity of sonography in detection of hepatocellular carcinoma in advanced liver cirrhosis: accuracy of pretransplantation sonography in 118 patients. Eur Radiol. 2003 Jul;13(7):1693–8. [PubMed: 12835987]
153.
Liu YI, Kamaya A, Jeffrey RB, et al. Multidetector computed tomography triphasic evaluation of the liver before transplantation: importance of equilibrium phase washout and morphology for characterizing hypervascular lesions. J Comput Assist Tomogr. 2012 Mar–Apr;36(2):213–9. [PubMed: 22446362]
154.
Liu YI, Shin LK, Jeffrey RB, et al. Quantitatively defining washout in hepatocellular carcinoma. AJR Am J Roentgenol. 2013 Jan;200(1):84–9. [PubMed: 23255745]
155.
Lu CH, Chen CL, Cheng YF, et al. Correlation between imaging and pathologic findings in explanted livers of hepatocellular carcinoma cases. Transplant Proc. 2010 Apr;42(3):830–3. [PubMed: 20430183]
156.
Luca A, Caruso S, Milazzo M, et al. Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants. Eur Radiol. 2010 Apr;20(4):898–907. [Erratum appears in Eur Radiol. 2011 Jul;21(7):1574 Note: Grutttadauria, Salvatore [corrected to Gruttadauria, Salvatore]] [PubMed: 19802612]
157.
Luo BM, Wen YL, Yang HY, et al. Differentiation between malignant and benign nodules in the liver: use of contrast C3-MODE technology. World J Gastroenterol. 2005 Apr 28;11(16):2402–7. [PMC free article: PMC4305625] [PubMed: 15832408]
158.
Luo W, Numata K, Kondo M, et al. Sonazoid-enhanced ultrasonography for evaluation of the enhancement patterns of focal liver tumors in the late phase by intermittent imaging with a high mechanical index. J Ultrasound Med. 2009 Apr;28(4):439–48. [PubMed: 19321671]
159.
Luo W, Numata K, Morimoto M, et al. Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT. Radiology. 2009 Apr;251(1):287–95. [PubMed: 19221060]
160.
Luo W, Numata K, Morimoto M, et al. Three-dimensional contrast-enhanced sonography of vascular patterns of focal liver tumors: pilot study of visualization methods. AJR Am J Roentgenol. 2009 Jan;192(1):165–73. [PubMed: 19098197]
161.
Lv P, Lin XZ, Chen K, et al. Spectral CT in patients with small HCC: investigation of image quality and diagnostic accuracy. Eur Radiol. 2012 Oct;22(10):2117–24. [PubMed: 22618521]
162.
Lv P, Lin XZ, Li J, et al. Differentiation of small hepatic hemangioma from small hepatocellular carcinoma: recently introduced spectral CT method. Radiology. 2011 Jun;259(3):720–9. [PubMed: 21357524]
163.
Maetani YS, Ueda M, Haga H, et al. Hepatocellular carcinoma in patients undergoing living-donor liver transplantation. Accuracy of multidetector computed tomography by viewing images on digital monitors. Intervirology. 2008;51(Suppl 1):46–51. [PubMed: 18544948]
164.
Marin D, Catalano C, De Filippis G, et al. Detection of hepatocellular carcinoma in patients with cirrhosis: added value of coronal reformations from isotropic voxels with 64-MDCT. AJR Am J Roentgenol. 2009 Jan;192(1):180–7. [PubMed: 19098199]
165.
Marin D, Di Martino M, Guerrisi A, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology. 2009 Apr;251(1):85–95. [PubMed: 19332848]
166.
Marrero JA, Hussain HK, Nghiem HV, et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl. 2005 Mar;11(3):281–9. [PubMed: 15719410]
167.
Matsuo M, Kanematsu M, Itoh K, et al. Detection of malignant hepatic tumors: comparison of gadolinium-and ferumoxide-enhanced MR imaging. AJR Am J Roentgenol. 2001 Sep;177(3):637–43. [PubMed: 11517061]
168.
Mita K, Kim SR, Kudo M, et al. Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol. 2010 Sep 7;16(33):4187–92. [PMC free article: PMC2932924] [PubMed: 20806437]
169.
Mok TSK, Yu SCH, Lee C, et al. False-negative rate of abdominal sonography for detecting hepatocellular carcinoma in patients with hepatitis B and elevated serum alpha-fetoprotein levels. AJR Am J Roentgenol. 2004 Aug;183(2):453–8. [PubMed: 15269040]
170.
Monzawa S, Ichikawa T, Nakajima H, et al. Dynamic CT for detecting small hepatocellular carcinoma: usefulness of delayed phase imaging. AJR Am J Roentgenol. 2007 Jan;188(1):147–53. [PubMed: 17179357]
171.
Mori K, Yoshioka H, Takahashi N, et al. Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late, and whole triple arterial phase imaging. AJR Am J Roentgenol. 2005 Jan;184(1):63–9. [PubMed: 15615952]
172.
Moriyasu F, Itoh K. Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 2009 Jul;193(1):86–95. [PubMed: 19542399]
173.
Mortele KJ, De Keukeleire K, Praet M, et al. Malignant focal hepatic lesions complicating underlying liver disease: dual-phase contrast-enhanced spiral CT sensitivity and specificity in orthotopic liver transplant patients. Eur Radiol. 2001;11(9):1631–8. [PubMed: 11511882]
174.
Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology. 2010 Jul;256(1):151–8. [PubMed: 20574092]
175.
Murakami T, Kim T, Kawata S, et al. Evaluation of optimal timing of arterial phase imaging for the detection of hypervascular hepatocellular carcinoma by using triple arterial phase imaging with multidetector-row helical computed tomography. Invest Radiol. 2003 Aug;38(8):497–503. [PubMed: 12874516]
176.
Murakami T, Kim T, Takamura M, et al. Hypervascular hepatocellular carcinoma: detection with double arterial phase multi-detector row helical CT. Radiology. 2001 Mar;218(3):763–7. [PubMed: 11230652]
177.
Nagaoka S, Itano S, Ishibashi M, et al. Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int. 2006 Sep;26(7):781–8. [PubMed: 16911459]
178.
Nakamura H, Ito N, Kotake F, et al. Tumor-detecting capacity and clinical usefulness of SPIO-MRI in patients with hepatocellular carcinoma. J Gastroenterol. 2000;35(11):849–55. [PubMed: 11085494]
179.
Nakamura Y, Tashiro H, Nambu J, et al. Detectability of hepatocellular carcinoma by gadoxetate disodium-enhanced hepatic MRI: Tumor-by-tumor analysis in explant livers. J Magn Reson Imaging. 2013;37(3):684–91. [PubMed: 23055436]
180.
Nakayama A, Imamura H, Matsuyama Y, et al. Value of lipiodol computed tomography and digital subtraction angiography in the era of helical biphasic computed tomography as preoperative assessment of hepatocellular carcinoma. Ann Surg. 2001 Jul;234(1):56–62. [PMC free article: PMC1421948] [PubMed: 11420483]
181.
Noguchi Y, Murakami T, Kim T, et al. Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. AJR Am J Roentgenol. 2003 Feb;180(2):455–60. [PubMed: 12540451]
182.
Noguchi Y, Murakami T, Kim T, et al. Detection of hypervascular hepatocellular carcinoma by dynamic magnetic resonance imaging with double-echo chemical shift in-phase and opposed-phase gradient echo technique: comparison with dynamic helical computed tomography imaging with double arterial phase. J Comput Assist Tomogr. 2002 Nov–Dec;26(6):981–7. [PubMed: 12488747]
183.
Numata K, Fukuda H, Miwa H, et al. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma. Eur J Radiol. 2014 [PubMed: 24176532]
184.
Onishi H, Kim T, Imai Y, et al. Hypervascular hepatocellular carcinomas: detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT. Eur Radiol. 2012 Apr;22(4):845–54. [PubMed: 22057248]
185.
Ooi C-C, Low S-C, Schneider-Kolsky M, et al. Diagnostic accuracy of contrast-enhanced ultrasound in differentiating benign and malignant focal liver lesions: a retrospective study. J Med Imaging Radiat Oncol. 2010 Oct;54(5):421–30. [PubMed: 20958940]
186.
Ooka Y, Kanai F, Okabe S, et al. Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magn Reson Imaging. 2013;31(5):748–54. Epub 2012 Dec 5. [PubMed: 23218794]
187.
Park G, Kim YK, Kim CS, et al. Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol. 2010 Dec;83(996):1010–6. [PMC free article: PMC3473616] [PubMed: 20682591]
188.
Park JH, Kim SH, Park HS, et al. Added value of 80 kVp images to averaged 120 kVp images in the detection of hepatocellular carcinomas in liver transplantation candidates using dual-source dual-energy MDCT: results of JAFROC analysis. Eur J Radiol. 2011 Nov;80(2):e76–85. [PubMed: 20875937]
189.
Park J-W, Kim JH, Kim SK, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008 Dec;49(12):1912–21. [PubMed: 18997056]
190.
Park MJ, Kim YK, Lee MH, et al. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (≤ 2.0 cm) in patients with hepatitis-induced liver cirrhosis. Acta Radiol. 2013;54(2):127–36. [PubMed: 23148300]
191.
Park M-S, Kim S, Patel J, et al. Hepatocellular carcinoma: detection with diffusion-weighted versus contrast-enhanced magnetic resonance imaging in pretransplant patients. Hepatology. 2012 Jul;56(1):140–8. [PubMed: 22370974]
192.
Park Y, Kim SH, Kim SH, et al. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience. Korean J Radiol. 2010 Jul–Aug;11(4):433–40. [PMC free article: PMC2893314] [PubMed: 20592927]
193.
Paul SB, Gulati MS, Sreenivas V, et al. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology. 2007;72(Suppl 1):117–23. [PubMed: 18087192]
194.
Pauleit D, Textor J, Bachmann R, et al. Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology. 2002 Jan;222(1):73–80. [PubMed: 11756708]
195.
Pei XQ, Liu LZ, Xiong YH, et al. Quantitative analysis of contrast-enhanced ultrasonography: Differentiating focal nodular hyperplasia from hepatocellular carcinoma. Br J Radiol. 2013 Mar;86(1023):20120536. Epub 2013 Feb 7. [PMC free article: PMC3608056] [PubMed: 23392189]
196.
Peterson MS, Baron RL, Marsh JW Jr, et al. Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: epidemiology and CT-based tumor detection rate in 430 cases with surgical pathologic correlation. Radiology. 2000 Dec;217(3):743–9. [PubMed: 11110938]
197.
Petruzzi N, Mitchell D, Guglielmo F, et al. Hepatocellular carcinoma likelihood on MRI exams. Evaluation of a standardized categorization System. Acad Radiol. 2013 Jun;20(6):694–8. Epub 2013 Mar 28. [PubMed: 23541479]
198.
Piana G, Trinquart L, Meskine N, et al. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol. 2011 Jul;55(1):126–32. [PubMed: 21145857]
199.
Pitton MB, Kloeckner R, Herber S, et al. MRI versus 64-row MDCT for diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2009 Dec 28;15(48):6044–51. [PMC free article: PMC2797660] [PubMed: 20027676]
200.
Pocha C, Dieperink E, McMaken KA, et al. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography - A randomised study. Alimentary Pharmacology and Therapeutics. 2013;38(3):303–12. [PubMed: 23750991]
201.
Pozzi Mucelli RM, Como G, Del Frate C, et al. Multidetector CT with double arterial phase and high-iodine-concentration contrast agent in the detection of hepatocellular carcinoma. Radiol Med (Torino). 2006 Mar;111(2):181–91. [PubMed: 16671376]
202.
Pugacheva O, Matsui O, Kozaka K, et al. Detection of small hypervascular hepatocellular carcinomas by EASL criteria: comparison with double-phase CT during hepatic arteriography. Eur J Radiol. 2011 Dec;80(3):e201–6. [PubMed: 20855175]
203.
Quaia E, Alaimo V, Baratella E, et al. The added diagnostic value of 64-row multidetector CT combined with contrast-enhanced US in the evaluation of hepatocellular nodule vascularity: implications in the diagnosis of malignancy in patients with liver cirrhosis. Eur Radiol. 2009 Mar;19(3):651–63. [PubMed: 18815790]
204.
Quaia E, Bertolotto M, Calderan L, et al. US characterization of focal hepatic lesions with intermittent high-acoustic-power mode and contrast material. Acad Radiol. 2003 Jul;10(7):739–50. [PubMed: 12862283]
205.
Rhee H, Kim MJ, Park MS, et al. Differentiation of early hepatocellular carcinoma from benign hepatocellular nodules on gadoxetic acid-enhanced MRI. Br J Radiol. 2012 Oct;85(1018):e837–44. [PMC free article: PMC3474012] [PubMed: 22553295]
206.
Rickes S, Schulze S, Neye H, et al. Improved diagnosing of small hepatocellular carcinomas by echo-enhanced power Doppler sonography in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2003 Aug;15(8):893–900. [PubMed: 12867800]
207.
Rimola J, Forner A, Tremosini S, et al. Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol. 2012 Jun;56(6):1317–23. [PubMed: 22314420]
208.
Rizvi S, Camci C, Yong Y, et al. Is post-Lipiodol CT better than i.v. contrast CT scan for early detection of HCC? A single liver transplant center experience. Transplant Proc. 2006 Nov;38(9):2993–5. [PubMed: 17112883]
209.
Rode A, Bancel B, Douek P, et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr. 2001 May–Jun;25(3):327–36. [PubMed: 11351179]
210.
Ronzoni A, Artioli D, Scardina R, et al. Role of MDCT in the diagnosis of hepatocellular carcinoma in patients with cirrhosis undergoing orthotopic liver transplantation. AJR Am J Roentgenol. 2007 Oct;189(4):792–8. [PubMed: 17885047]
211.
Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut. 2010 May;59(5):638–44. [PubMed: 19951909]
212.
Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology. 2011 Dec;261(3):834–44. [PubMed: 21998047]
213.
Schima W, Hammerstingl R, Catalano C, et al. Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: Effect of contrast material flow rate. AJR Am J Roentgenol. 2006;186(6):1571–9. [PubMed: 16714645]
214.
Secil M, Obuz F, Altay C, et al. The role of dynamic subtraction MRI in detection of hepatocellular carcinoma. Diagn Interv Radiol. 2008 Dec;14(4):200–4. [PubMed: 19061165]
215.
Seitz K, Bernatik T, Strobel D, et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI--a prospective comparison in 269 patients. Ultraschall Med. 2010 Oct;31(5):492–9. [PubMed: 20652854]
216.
Seitz K, Strobel D, Bernatik T, et al. Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreilandertreffen 2008, Davos. Ultraschall Med. 2009 Aug;30(4):383–9. [PubMed: 19688670]
217.
Serste T, Barrau V, Ozenne V, et al. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology. 2012 Mar;55(3):800–6. [PubMed: 22006503]
218.
Shah SA, Tan JC, McGilvray ID, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation. 2006 Jun 27;81(12):1633–9. [PubMed: 16794527]
219.
Simon G, Link TM, Wortler K, et al. Detection of hepatocellular carcinoma: comparison of Gd-DTPA- and ferumoxides-enhanced MR imaging. Eur Radiol. 2005 May;15(5):895–903. [PubMed: 15800773]
220.
Singh P, Erickson RA, Mukhopadhyay P, et al. EUS for detection of the hepatocellular carcinoma: results of a prospective study. Gastrointest Endosc. 2007 Aug;66(2):265–73. [PubMed: 17543307]
221.
Sofue K, Tsurusaki M, Kawasaki R, et al. Evaluation of hypervascular hepatocellular carcinoma in cirrhotic liver: comparison of different concentrations of contrast material with multi-detector row helical CT--a prospective randomized study. Eur J Radiol. 2011 Dec;80(3):e237–42. [PubMed: 21067880]
222.
Sørensen M, Frisch K, Bender D, et al. The potential use of 2-[ 18F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2011;38(9):1723–31. [PMC free article: PMC3152607] [PubMed: 21553087]
223.
Strobel D, Raeker S, Martus P, et al. Phase inversion harmonic imaging versus contrast-enhanced power Doppler sonography for the characterization of focal liver lesions. Int J Colorectal Dis. 2003 Jan;18(1):63–72. [PubMed: 12458384]
224.
Sugimoto K, Moriyasu F, Saito K, et al. Comparison of Kupffer-phase Sonazoid-enhanced sonography and hepatobiliary-phase gadoxetic acid-enhanced magnetic resonance imaging of hepatocellular carcinoma and correlation with histologic grading. J Ultrasound Med. 2012 Apr;31(4):529–38. [PubMed: 22441909]
225.
Sugimoto K, Moriyasu F, Shiraishi J, et al. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol. 2012 Jun;22(6):1205–13. [PubMed: 22270142]
226.
Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol. 2004;39(10):961–8. [PubMed: 15549449]
227.
Suh YJ, Kim M-J, Choi J-Y, et al. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. AJR Am J Roentgenol. 2011 Jul;197(1):W44–52. [PubMed: 21700994]
228.
Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (≤ 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol. 2010 Feb;45(2):96–103. [PubMed: 20057319]
229.
Sun L, Guan YS, Pan WM, et al. Metabolic restaging of hepatocellular carcinoma using whole-body F-FDG PET/CT. World J Hepatol. 2009 Oct 31;1(1):90–7. [PMC free article: PMC2998956] [PubMed: 21160970]
230.
Suzuki S, Iijima H, Moriyasu F, et al. Differential diagnosis of hepatic nodules using delayed parenchymal phase imaging of levovist contrast ultrasound: comparative study with SPIO-MRI. Hepatol Res. 2004 Jun;29(2):122–6. [PubMed: 15163434]
231.
Takahashi M, Maruyama H, Shimada T, et al. Characterization of hepatic lesions (≤ 30 mm) with liver-specific contrast agents: a comparison between ultrasound and magnetic resonance imaging. Eur J Radiol. 2013;82(1):75–84. [PubMed: 23116806]
232.
Talbot J, Fartoux L, Balogova S, et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010 Nov;51(11):1699–706. [PubMed: 20956466]
233.
Talbot J, Gutman F, Fartoux L, et al. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1285–9. [PubMed: 16802155]
234.
Tanaka O, Ito H, Yamada K, et al. Higher lesion conspicuity for SENSE dynamic MRI in detecting hypervascular hepatocellular carcinoma: analysis through the measurements of liver SNR and lesion-liver CNR comparison with conventional dynamic MRI. Eur Radiol. 2005 Dec;15(12):2427–34. [PubMed: 16041592]
235.
Tanaka S, Ioka T, Oshikawa O, et al. Dynamic sonography of hepatic tumors. AJR Am J Roentgenol. 2001 Oct;177(4):799–805. [PubMed: 11566675]
236.
Tang Y, Yamashita Y, Arakawa A, et al. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging. AJR Am J Roentgenol. 1999 Jun;172(6):1547–54. [PubMed: 10350287]
237.
Tanimoto A, Yuasa Y, Jinzaki M, et al. Routine MR imaging protocol with breath-hold fast scans: diagnostic efficacy for focal liver lesions. Radiat Med. 2002 Jul–Aug;20(4):169–79. [PubMed: 12296432]
238.
Teefey SA, Hildeboldt CC, Dehdashti F, et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology. 2003 Feb;226(2):533–42. [PubMed: 12563151]
239.
Toyota N, Nakamura Y, Hieda M, et al. Diagnostic capability of gadoxetate disodium-enhanced liver MRI for diagnosis of hepatocellular carcinoma: Comparison with multi-detector CT. Hiroshima Journal of Medical Sciences. 2013;62(3):55–61. [PubMed: 24279123]
240.
Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011 Dec;54(6):1987–97. [PubMed: 22144108]
241.
Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999 Nov;94(11):3314–9. [PubMed: 10566736]
242.
Tsurusaki M, Semelka RC, Uotani K, et al. Prospective comparison of high- and low-spatial-resolution dynamic MR imaging with sensitivity encoding (SENSE) for hypervascular hepatocellular carcinoma. Eur Radiol. 2008 Oct;18(10):2206–12. [PubMed: 18446347]
243.
Valls C, Cos M, Figueras J, et al. Pretransplantation diagnosis and staging of hepatocellular carcinoma in patients with cirrhosis: value of dual-phase helical CT. AJR Am J Roentgenol. 2004 Apr;182(4):1011–7. [PubMed: 15039179]
244.
Van Thiel DH, Yong S, Li SD, et al. The development of de novo hepatocellular carcinoma in patients on a liver transplant list: frequency, size, and assessment of current screening methods. Liver Transpl. 2004 May;10(5):631–7. [PubMed: 15108254]
245.
Vandecaveye V, De Keyzer F, Verslype C, et al. Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol. 2009 Oct;19(10):2456–66. [PubMed: 19440718]
246.
Verhoef C, Valkema R, de Man RA, et al. Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography. Liver. 2002 Feb;22(1):51–6. [PubMed: 11906619]
247.
Wagnetz U, Atri M, Massey C, et al. Intraoperative ultrasound of the liver in primary and secondary hepatic malignancies: comparison with preoperative 1.5-T MRI and 64-MDCT. AJR Am J Roentgenol. 2011 Mar;196(3):562–8. [PubMed: 21343497]
248.
Wang JH, Chang KC, Kee KM, et al. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013 Mar;108(3):416–24. [PubMed: 23318478]
249.
Wang J-H, Lu S-N, Hung C-H, et al. Small hepatic nodules (≤ 2 cm) in cirrhosis patients: characterization with contrast-enhanced ultrasonography. Liver Int. 2006 Oct;26(8):928–34. [PubMed: 16953832]
250.
Wang ZL, Tang J, Weskott HP, et al. Undetermined focal liver lesions on gray-scale ultrasound in patients with fatty liver: characterization with contrast-enhanced ultrasound. J Gastroenterol Hepatol. 2008 Oct;23(10):1511–9. [PubMed: 18713302]
251.
Wolfort RM, Papillion PW, Turnage RH, et al. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade. Int Surg. 2010 Jan–Mar;95(1):67–75. [PubMed: 20480845]
252.
Wu H-b, Wang Q-s, Li B-y, et al. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med. 2011 Dec;36(12):1092–7. [PubMed: 22064078]
253.
Wudel LJ Jr, Delbeke D, Morris D, et al. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg. 2003 Feb;69(2):117–24. discussion 24–6. [PubMed: 12641351]
254.
Xiao X-g, Han X, Shan W-d, et al. Multi-slice CT angiography by triple-phase enhancement in preoperative evaluation of hepatocellular carcinoma. Chin Med J (Engl). 2005 May 20;118(10):844–9. [PubMed: 15989766]
255.
Xu HX, Lu MD, Liu LN, et al. Discrimination between neoplastic and non-neoplastic lesions in cirrhotic liver using contrast-enhanced ultrasound. Br J Radiol. 2012 Oct;85(1018):1376–84. [PMC free article: PMC3474036] [PubMed: 22553290]
256.
Xu H-X, Xie X-Y, Lu M-D, et al. Contrast-enhanced sonography in the diagnosis of small hepatocellular carcinoma ≤ 2 cm. J Clin Ultrasound. 2008 Jun;36(5):257–66. [PubMed: 18088056]
257.
Xu P-J, Yan F-H, Wang J-H, et al. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis. J Magn Reson Imaging. 2009 Feb;29(2):341–9. [PubMed: 19161186]
258.
Xu P-J, Yan F-H, Wang J-H, et al. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr. 2010 Jul;34(4):506–12. [PubMed: 20657216]
259.
Yamamoto K, Shiraki K, Deguchi M, et al. Diagnosis of hepatocellular carcinoma using digital subtraction imaging with the contrast agent, Levovist: comparison with helical CT, digital subtraction angiography, and US angiography. Oncol Rep. 2002 Jul–Aug;9(4):789–92. [PubMed: 12066210]
260.
Yamamoto Y, Nishiyama Y, Kameyama R, et al. Detection of hepatocellular carcinoma using 11C-choline PET: Comparison with 18F-FDG PET. J Nucl Med. 2008 Aug;49(8):1245–8. [PubMed: 18632827]
261.
Yan FH, Shen JZ, Li RC, et al. Enhancement patterns of small hepatocellular carcinoma shown by dynamic MRI and CT. Hepatobiliary Pancreat Dis Int. 2002 Aug;1(3):420–4. [PubMed: 14607719]
262.
Yoo HJ, Lee JM, Lee JY, et al. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver. Invest Radiol. 2009 Dec;44(12):800–7. [PubMed: 19838119]
263.
Yoo SH, Choi JY, Jang JW, et al. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma. Ann Surg Oncol. 2013;20(9):2893–900. [PubMed: 23649931]
264.
Yoon KT, Kim JK, Kim DY, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology. 2007;72(Suppl 1):104–10. [PubMed: 18087190]
265.
Yoshioka H, Takahashi N, Yamaguchi M, et al. Double arterial phase dynamic MRI with sensitivity encoding (SENSE) for hypervascular hepatocellular carcinomas. J Magn Reson Imaging. 2002 Sep;16(3):259–66. [PubMed: 12205581]
266.
Youk JH, Lee JM, Kim CS. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents. AJR Am J Roentgenol. 2004 Oct;183(4):1049–54. [PubMed: 15385303]
267.
Yu JS, Chung JJ, Kim JH, et al. Small hypervascular hepatocellular carcinomas: value of “washout” on gadolinium-enhanced dynamic MR imaging compared to superparamagnetic iron oxide-enhanced imaging. Eur Radiol. 2009 Nov;19(11):2614–22. [PubMed: 19513719]
268.
Yu JS, Kim KW, Park MS, et al. Transient peritumoral enhancement during dynamic MRI of the liver: Cavernous hemangioma versus hepatocellular carcinoma. J Comput Assist Tomogr. 2002 May–Jun;26(3):411–7. [PubMed: 12016371]
269.
Yu JS, Lee JH, Chung JJ, et al. Small hypervascular hepatocellular carcinoma: limited value of portal and delayed phases on dynamic magnetic resonance imaging. Acta Radiol. 2008 Sep;49(7):735–43. [PubMed: 18608015]
270.
Yu MH, Kim JH, Yoon JH, et al. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: Diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI. AJR Am J Roentgenol. 2013;201(3):675–83. [PubMed: 23971463]
271.
Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011 Feb;9(2):161–7. [PubMed: 20920597]
272.
Yu Y, He N, Sun K, et al. Differentiating hepatocellular carcinoma from angiomyolipoma of the liver with CT spectral imaging: A preliminary study. Clin Radiol. 2013;68(9):e491–e7. [PubMed: 23702491]
273.
Yu Y, Lin X, Chen K, et al. Hepatocellular carcinoma and focal nodular hyperplasia of the liver: differentiation with CT spectral imaging. Eur Radiol. 2013 Jun;23(6):1660–8. Epub 2013 Jan 10. [PubMed: 23306709]
274.
Yukisawa S, Okugawa H, Masuya Y, et al. Multidetector helical CT plus superparamagnetic iron oxide-enhanced MR imaging for focal hepatic lesions in cirrhotic liver: a comparison with multi-phase CT during hepatic arteriography. Eur J Radiol. 2007 Feb;61(2):279–89. [PubMed: 17070663]
275.
Zacherl J, Pokieser P, Wrba F, et al. Accuracy of multiphasic helical computed tomography and intraoperative sonography in patients undergoing orthotopic liver transplantation for hepatoma: what is the truth? Ann Surg. 2002 Apr;235(4):528–32. [PMC free article: PMC1422468] [PubMed: 11923609]
276.
Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004 Jul;130(7):417–22. [PubMed: 15042359]
277.
Zhao H, Yao JL, Han MJ, et al. Multiphase hepatic scans with multirow-detector helical CT in detection of hypervascular hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2004 May;3(2):204–8. [PubMed: 15138110]
278.
Zhao H, Yao J-L, Wang Y, et al. Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning. World J Gastroenterol. 2007 Feb 28;13(8):1252–6. [PMC free article: PMC4147003] [PubMed: 17451209]
279.
Zhao H, Zhou K-R, Yan F-H. Role of multiphase scans by multirow-detector helical CT in detecting small hepatocellular carcinoma. World J Gastroenterol. 2003 Oct;9(10):2198–201. [PMC free article: PMC4656462] [PubMed: 14562377]
280.
Zheng X-H, Guan Y-S, Zhou X-P, et al. Detection of hypervascular hepatocellular carcinoma: Comparison of multi-detector CT with digital subtraction angiography and Lipiodol CT. World J Gastroenterol. 2005 Jan 14;11(2):200–3. [PMC free article: PMC4205401] [PubMed: 15633215]
281.
Zhou K-R, Yan F-H, Tu B-W. Arterial phase of biphase enhancement spiral CT in diagnosis of small hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2002 Feb;1(1):68–71. [PubMed: 14607626]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (7.7M)

Other titles in these collections

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...